| YEDA RESEARCH AND DEVELOPMENT CO. LTD. Patent applications |
| Patent application number | Title | Published |
|---|
| 20120134977 | PRODRUGS CONTAINING ALBUMIN BINDING PROBE - The present invention provides albumin-binding probes capable of reversibly linking to short-lived amino-containing drugs and non-covalently associating with albumin in-vivo, thereby converting said drugs into inactive reactivable prodrugs having prolonged lifetime in-vivo. The invention further provides conjugates of said probes with amino-containing drugs, as well as pharmaceutical compositions and uses thereof. | 05-31-2012 |
| 20120101365 | ASSESSMENT OF BLOOD-BRAIN BARRIER DISRUPTION - A method of analyzing a blood-brain bather of a subject is disclosed. A detectable dose of an MRI contrast agent is administered to the subject, and a plurality of magnetic resonance images of the subject's brain are acquired over a predetermined time-period. Two or more of the magnetic resonance images are compared thereamongst so as to determine variations in concentration of the contrast agent in the brain, and blood-brain barrier function is assessed based on the variations. | 04-26-2012 |
| 20120093842 | CHIMERIC RECEPTOR GENES AND CELLS TRANSFORMED THEREWITH - Chimeric receptor genes suitable for endowing lymphocytes with antibody-type specificity include a first gene segment encoding a single-chain Fv domain of a specific antibody and a second gene segment encoding all or part of the transmembrane and cytoplasmic domains, and optionally the extracellular domain, of an immune cell-triggering molecule. The chimeric receptor gene, when transfected to immune cells, expresses the antibody-recognition site and the immune cell-triggering moiety into one continuous chain. The transformed lymphocytes are useful in therapeutic treatment methods. | 04-19-2012 |
| 20120086850 | SUPER RESOLUTION FROM A SINGLE SIGNAL - A method implementable on a computing device includes exploiting data redundancy to combine high frequency information from at least two different scales of an input signal to generate a super resolution version of said input signal. An alternative method includes exploiting recurrence of data from an input signal in at least two different scales of at least one reference signal to extract and to combine high frequency information from a plurality of scales of said at least one reference signal to generate a super resolution version of said input signal. An alternative method includes generating a super resolution version of a single input video sequence in at least the temporal dimension by exploiting data recurrence within the input video sequence or with respect to an external database of example video sequences. A signal may be an image, a video sequence, an audio signal, etc. | 04-12-2012 |
| 20120083477 | PROTEASOME INHIBITORS AND USES THEREOF - A method of treating a disease in which inhibiting of a proteasome is advantageous is provided. The method comprises administering to the subject a therapeutically effective amount of a compound which binds to a proteasome of a cell, the compound comprising a copper bound to a ligand, the ligand being configured such that upon binding to the proteasome, the copper interacts with cysteine 31 of a Beta2 subunit of the proteasome and further interacts with cysteine 118 of a Beta3 subunit of the proteasome, thereby treating the disease. Additional novel proteasome inhibitors are also provided as well as methods of identifying proteasome inhibitors. | 04-05-2012 |
| 20120070449 | METHODS OF TREATING INFLAMMATION - A method of treating an inflammation in a subject in need thereof is disclosed. The method comprising administering to the subject an agent capable of down-regulating an activity or expression of CD151 in a lymphocyte, with the proviso that the agent is not CCL2, thereby treating the inflammation. | 03-22-2012 |
| 20120060418 | CATALYTIC GASIFICATION OF ORGANIC MATTER IN SUPERCRITICAL WATER - A catalyst system including at least one metal and an oxide support, said oxide support including at least one of Al | 03-15-2012 |
| 20120058945 | NEUROPROTECTIVE IRON CHELATORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM - Novel iron chelators exhibiting neuroprotective and good transport properties are useful in iron chelation therapy for treatment of a disease, disorder or condition associated with iron overload and oxidative stress, e.g., a neurodegenerative or cerebrovascular disease or disorder, a neoplastic disease, hemochromatosis, thalassemia, a cardiovascular disease, diabetes, an inflammatory disorder, anthracycline cardiotoxicity, a viral infection, a protozoal infection, a yeast infection, retarding aging, and prevention and/or treatment of skin aging and skin protection against sunlight and/or UV light. The iron chelator function is provided by a 8-hydroxyquinoline, a hydroxypyridinone or a hydroxamate moiety. The neuroprotective function is imparted to the compound, e.g., by a neuroprotective peptide. A combined antiapoptotic and neuroprotective function is provided by a propargyl group. | 03-08-2012 |
| 20120045411 | SHORT BETA-DEFENSIN-DERIVED PEPTIDES - The invention is directed to beta-defensin-derived peptides and their use in modulating the activity of hematopoietic cells and other CXCR4-expressing cells. Specifically, the invention provides compositions and methods useful in the treatment of cancer. The invention further provides compositions and methods useful for promoting mobilization and transplantation of hematopoietic stem cells and progenitor cells. | 02-23-2012 |
| 20120040993 | NEUROPROTECTIVE MULTIFUNCTIONAL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM - Multifunctional compounds are provided, comprising two or more functional moieties selected from: (i) a moiety that imparts an iron chelator function; (ii) a moiety that imparts a neuroprotective function; (iii) a moiety that imparts combined antiapoptotic, neuroprotective and/or neurorestorative functions; (iv) a moiety that imparts brain MAO inhibition, preferably with little or no MAO inhibition in liver and small intestine; (v) a moiety that imparts cholinesterase inhibitory function; and (vi) a moiety that imparts an N-methyl-D-aspartic acid receptor (NMDAR) inhibition, and pharmaceutically acceptable salts and optical isomers thereof. The multifunctional compounds are useful in the treatment or prevention of diseases, disorders or conditions that can be prevented and/or treated by iron chelation therapy, and/or neuroprotection and/or neurorestoration, and/or apoptosis inhibition and/or MAO inhibition and/or cholinesterase inhibition and/or NMADR inhibition. The present invention encompasses compounds of the formulas I to VI. | 02-16-2012 |
| 20120028887 | LIPOPEPTIDE INHIBITORS OF HIV-1 - The invention provides lipophilic conjugates comprising a short isolated peptide coupled to a hydrophobic moiety, the peptide comprising a sequence derived from the HIV-1 gp41 N-terminal heptad repeat domain, said peptide after conjugation to the hydrophobic moiety possesses anti-fusogenic activity higher than prior to conjugation. The lipophilic conjugates are suitable for treatment of infections caused by human and non-human retroviruses, especially HIV. | 02-02-2012 |
| 20120010836 | ELECTROMAGNETIC RADIATION MAPPING SYSTEM - Apparatus for radiation mapping of a region comprises a spectrum analyzer for analyzing a local radiation field according to wavelength, and a positioning unit for obtaining a position reading to correlate with said local radiation field, thereby to provide said radiation mapping. The results may be provided as layers to a map, and different layers may be provided for different frequencies and different times of the day. | 01-12-2012 |
| 20120003236 | ANTIBODIES AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME USEFUL FOR INHIBITING ACTIVITY OF METALLOPROTEINS - A method of producing a metalloprotein inhibitor, the method comprising generating antibodies directed at a composition including a metal ion-bound chelator, wherein the composition is selected having structural and electronic properties similar to a functional domain of the metalloprotein, thereby producing the metalloprotein inhibitor. | 01-05-2012 |
| 20110314813 | SOLAR RECEIVER SYSTEM - A solar receiver is provided. The solar receiver may include a receiver housing with front and rear ends. The solar receiver may also include a window configured to allow radiation to pass therethrough. The window may be mounted at the front end and project within the housing. The solar receiver may also include a receiver chamber defined between the housing and the window. The receiver chamber may include a working fluid inlet for ingress of working fluid to be heated therewithin, and a working fluid outlet for egress therethrough of the heated working fluid. The solar receiver may also include a solar radiation absorber configured for absorbing the radiation and heating the working fluid thereby. The absorber may be located within the receiver chamber and may surround at least a portion of the window. The solar radiation absorber may be formed with projections. | 12-29-2011 |
| 20110306503 | TEMPLATE-DEPENDENT NUCLEIC ACID POLYMERIZATION USING OLIGONUCLEOTIDE TRIPHOSPHATES BUILDING BLOCKS - A novel use of a template-dependent polymerase. The novel use is effected by employing the template-dependent polymerase for incorporating at least one oligonucleotide triphosphate onto a nascent oligonucleotide-3′-OH in a template-dependent manner. | 12-15-2011 |
| 20110301065 | IDENTIFYING ANTIGEN CLUSTERS FOR MONITORING A GLOBAL STATE OF AN IMMUNE SYSTEM - Method, system and an article of manufacture for clustering and thereby identifying predefined antigens reactive with undetermined immunoglobulins of sera derived from patient subjects in need of diagnosis of disease or monitoring of treatment. | 12-08-2011 |
| 20110294134 | METHODS AND KITS FOR DETERMINING A RISK TO DEVELOP CANCER, FOR EVALUATING AN EFFECTIVENESS AND DOSAGE OF CANCER THERAPY AND FOR CORRELATING BETWEEN AN ACTIVITY OF A DNA REPAIR ENZYME AND A CANCER - Methods and kits for (i) determining a risk of a subject to develop cancer; (ii) evaluating an effectiveness and dosage of cancer therapy administered to a cancer patient; and (iii) determining a presence of correlation or non-correlation between an activity of at least one DNA repair enzyme and at least one cancer, are disclosed. | 12-01-2011 |
| 20110293593 | SIVA 2 STABILIZATION - The present invention relates to modulation of SIVA2 stability by N-acetylglucosamine, phosphorylation of ubiquitination in treatment or prevention of diseases, disorders or conditions. | 12-01-2011 |
| 20110286932 | OPTICAL METHOD FOR THE DETECTION OF ALZHEIMER'S DISEASE - The present subject matter relates to a non-invasive optical imaging method for monitoring early pathological events specific to Alzheimer's disease (AD), such as the development, amount and location of amyloid plaques. The ability to monitor such events provides a basis for, among other things, AD diagnosis, prognosis and assessment of potential therapies. In addition, the present subject matter introduces novel methods for treating AD and retinal ailments associated with AD. Aβ-plaque detection in living brains is extremely limited, especially at high resolution; therefore the present invention is based on studies focusing on the eyes as an alternative to brain-derived tissue that can be imaged directly, repetitively and non-invasively. | 11-24-2011 |
| 20110283700 | SOLAR COMBINED CYCLE POWER SYSTEMS - A combined cycle power system is provided including at least one solar power plant including a concentrating dish configured to concentrate solar radiation; a solar receiver disposed and configured to utilize concentrated solar radiation for heating a first working fluid, and a first turbine configured for generating electricity by expansion therein of the heated first working fluid, and at least one recovery power plant including a heat recovery unit configured for utilizing exhaust heat of the first turbine to heat a second working fluid, and a second turbine configured for generating electricity by expansion therein of the heated second working fluid. | 11-24-2011 |
| 20110274647 | IL6R/IL6 Chimera for Therapy of Chemotherapy-Induced Peripheral Neuropathy - The invention relates to the use of IL-6R/IL-6 chimera in chemotherapy induced neuropathy. | 11-10-2011 |
| 20110268712 | Stem Cells Suitable for Transplantation, Their Preparation and Pharmaceutical Compositions Comprising Them - The present invention relates to stem cells suitable for transplantation and to methods for their preparation. | 11-03-2011 |
| 20110265224 | CONTROL OF SO2 METABOLISM IN PLANTS AND ITS APPLICATIONS - SO-transgenic plants overexpressing or lacking SO activity, having modified tolerance or susceptibility to toxicity of sulfite-producing substances, methods for their production and the use thereof for bioremediation of pollutants, as sentinel plants, for enhancing post-harvest quality of plants, plant tissues and plant products and for therapeutic applications. | 10-27-2011 |
| 20110239312 | METHODS OF DIAGNOSING AND TREATING MOTOR NEURON DISEASES - Use of an agent which upregulates an activity or amount of miRNA-9 or miRNA-9* is disclosed for the preparation of a medicament for the treatment of a motor neuron disease (MND). | 09-29-2011 |
| 20110236975 | GROWTH FACTOR WHICH ACTS THROUGH ERB B-4 RTK - The present invention provides for isolated polypeptides capable of binding ErbB-4. | 09-29-2011 |
| 20110224407 | Type I Interferon Antagonists - Disclosed in certain embodiments is a method of preparing a Type 1 interferon antagonist comprising modifying a Type 1 interferon at the site of interaction with the interferon receptor subunit IFNAR-1 such that the binding affinity of the interferon to the IFNAR-1 subunit is reduced as compared to the native interferon, and corresponding compositions and methods of treatment thereof. | 09-15-2011 |
| 20110212071 | ANTI THIRD PARTY CENTRAL MEMORY T CELLS, METHODS OF PRODUCING SAME AND USE OF SAME IN TRANSPLANTATION AND DISEASE TREATMENT - An isolated population of cells comprising non-GVHD inducing anti-third party cells having a central memory T-lymphocyte (Tcm) phenotype is provided. The cells being tolerance-inducing cells and capable of homing to the lymph nodes following transplantation. Methods of generating same, use of same and methods of treatment are also provided. | 09-01-2011 |
| 20110206706 | VACCINE AND METHOD FOR TREATMENT OF NEURODEGENERATIVE DISEASES - Methods and compositions are provided for treatment of neurodegenerative diseases in which there is accumulation of misfolded and/or aggregated proteins, excluding prion diseases. In particular, the invention relates to treatment of the neurodegenerative diseases Huntington's disease (HD), Alzheimer's disease (AD) or Parkinson's disease (PD), by administration of an agent selected from the group consisting of (i) Copolymer 1, (ii) a Copolymer 1-related peptide, (iii) a Copolymer 1-related polypeptide, and (iv) T cells activated with (i), (ii) or (iii). | 08-25-2011 |
| 20110195083 | CYCLIC V3 PEPTIDES FOR ANTI HIV-1 VACCINE - Isolated cyclic polypeptides useful as vaccinations for the treatment/prevention of HIV are disclosed. An exemplary peptide comprises at least 18 consecutive amino acids of a V3 domain of gp120, starting at position 303 and ending at position 322, the positioning being according to a numbering of the V3 domain of gp120 in a HXB2 strain, wherein amino acids at position 303 and 322 are bonded. Vaccines comprising same and methods of treating AIDS using same are also disclosed. | 08-11-2011 |
| 20110189202 | COMPOSITIONS COMPRISING SOLUBLE CD84 OR ANTI-CD84 ANTIBODIES AND METHODS FOR DIAGNOSING AND TREATING B-CLL - A method of diagnosing B-CLL in a subject in need thereof is provided. The method comprising determining in a biological sample of the subject a level of CD84 isoform C (SEQ ID NO: 30), wherein an increase in the level of the CD84 isoform C (SEQ ID NO: 30) beyond a predetermined threshold with respect to a level of the CD84 in a biological sample from a healthy individual is indicative of the B-CLL. | 08-04-2011 |
| 20110183437 | METHODS OF IDENTIFYING COMBINATIONS OF ANTIBODIES WITH AN IMPROVED ANTI-TUMOR ACTIVITY AND COMPOSITIONS AND METHODS USING THE ANTIBODIES - A method of identifying a combination of antibodies with a combined improved anti tumor activity is provided. The method comprising identifying at least two anti RTK antibodies capable of inducing synergistic endocytosis of the RTK in a cell expressing the RTK, thereby identifying the combination of antibodies with the combined improved anti-tumor activity. | 07-28-2011 |
| 20110177065 | METHODS OF TREATING/PREVENTING INFLAMMATION USING COMBINATION OF IL-1 ANTAGONIST AND IL-18 BINDING PROTEIN - The invention relates to the combined use of an IL-1 antagonist/inhibitor and IL-18 binding protein in inflammatory diseases. | 07-21-2011 |
| 20110171197 | PON POLYPEPTIDES, POLYNUCLEOTIDES ENCODING SAME AND COMPOSITIONS AND METHODS UTILIZING SAME - Isolated polynucleotides and polypeptides encoded therefrom are provided. These include mutated PON enzymes with increased, modified or substantially the same substrate specificity as compared to respective wild-type PON. Also provided are kits and methods using these enzymes. | 07-14-2011 |
| 20110165116 | PHARMACEUTICAL COMPOSITIONS COMPRISING CCL2 AND USE OF SAME FOR THE TREATMENT OF INFLAMMATION - A method of treating an inflammation in a subject thereof is provided. The method comprising administering to the subject a therapeutically effective amount of CCL2, thereby treating the inflammation. Also provided are pharmaceutical compositions and unit dosage forms which comprise CCL2 for the treatment of inflammation. | 07-07-2011 |
| 20110129937 | SEMICONDUCTOR DETECTOR FOR PEROXIDE-BASED EXPLOSIVES - A device for the detection of a peroxide-based explosive, in particular, triacetone triperoxide (TATP), which is based on a molecular controlled semiconductor resistor (MOCSER) and composed of at least one insulating or semi-insulating layer, at least one conducting semiconductor layer, two conducting pads and a layer of multifunctional organic molecules capable of adsorbing molecules of said peroxide-based explosive. Further is provided an array of semiconductor devices for the selective detection of a peroxide-based explosive, as well as a method for the selective detection of vapors of a peroxide-based explosive in a gaseous mixture using said array. The multifunctional organic molecules are from the group of cyclodextrins, thiols or alkylphosphonates with RPO(OH) 2 wherein R is an aliphatic hydrocarbyl with C6-C22. | 06-02-2011 |
| 20110123480 | CHIMERIC PROTEINS AND USES THEREOF - The present invention provides a chimeric protein capable of killing or modifying a cell expressing abnormally high levels of a ligand of a receptor of the TNF/NGF family, comprising the amino acid sequence of at least one polypeptide consisting of an extracellular portion of said receptor connected to an effector molecule. In addition the invention provides pharmaceutical compositions comprising said chimeric protein and use thereof. | 05-26-2011 |
| 20110117029 | WATER-SOLUBLE ANIONIC BACTERIOCHLOROPHYLL DERIVATIVES AND THEIR USES - The invention provides anionic water-soluble tetracyclic and pentacyclic bacteriochlorophyll derivatives (Bchls) containing at least one, preferably two or three, negatively charged groups and/or acidic groups that are converted to negatively charged groups at the physiological pH, preferably Bchls having a group COO<−>, COS<−>, SO3<−>, PO3<2−>, COOH, COSH, SO3H, and/or PO3H2 bound through an ester or amide bond to one or more of the positions 17<3>, 13<3>, and 3<2> of the tetracyclic or pentacyclic Bchl molecule, for photodynamic therapy and diagnosis. | 05-19-2011 |
| 20110104167 | Compositions and Methods for Diagnosing and Treating Insulin Resistance - A method of treating insulin resistance in a subject is provided. The method comprising administering to the subject a therapeutically effective amount of an agent capable of down-regulating phosphorylation of an IRS protein at at least one serine residue corresponding to amino acid 341, 412 and/or 413 of human IRS-1, thereby treating the insulin resistance in the subject. Also provided are methods and kits for diagnosing insulin resistance. | 05-05-2011 |
| 20110059536 | HEXAVALENT CHROMIUM DETECTOR - The present invention relates to a molecular-based system for the optical detection, quantification and detoxification of hexavalent chromium (Cr | 03-10-2011 |
| 20110044999 | IL-32 MODULATORS - The present invention relates to methods of screening for modulators of interleukin 32 (IL-32), to modulators of IL-32 and to their use. | 02-24-2011 |
| 20110040170 | ENDOSCOPIC IMAGING PHOTODYNAMIC THERAPY SYSTEM AND METHODS OF USE - The invention provides an endoscopic imaging photodynamic therapy system (EIPS) for focused tissue ablation by illumination of a photosensitizer drug in a target tissue, said system comprising an endoscopic assembly, a real-time imaging component for locating the target tissue and monitoring the ablation intervention, a therapeutic light system and, optionally, a drug delivery module, wherein said imaging component comprises a flexible transducer with an operative channel for insertion of a flexible light guide of the therapeutic light system and, optionally, a flexible drug delivery catheter of the drug delivery module. This EIPS may be used in various medical applications where tissue ablation is required and photodynamic therapy may be applied, in particular, in the treatment of extrauterine pregnancy (EUP). | 02-17-2011 |
| 20110035817 | SIVA 3, ITS PREPARATION AND USE - The present invention relates to a splice variant of SIVA, SIVA3, and to its use. | 02-10-2011 |
| 20110033488 | AGENTS AND METHODS FOR TREATMENT OF ANXIETY DISORDERS - Peptides derived from CNS-specific antigens, altered peptide ligands (APL) analogues of said peptides, T cells activated by such peptides, poly-YE, and any combination of said agents are useful for prevention, treatment and/or alleviation of anxiety disorders, particularly post-traumatic stress disorder, and for restoring BDNF levels in the brain of an individual after reduction of BDNF expression induced by stress. | 02-10-2011 |
| 20110009745 | Ultrasonically determining flow parameters of a fluid flowing through a passage, by using far-field analysis - Ultrasonically determining flow parameters of a fluid ( | 01-13-2011 |
| 20110003379 | CHIMERIC AUTOPROCESSING POLYPEPTIDES AND USES THEREOF - A chimeric polypeptide comprising an autoprocessing segment having an amino acid sequence being capable of auto-cleavage, a polynucleotide encoding such a polypeptide, and uses of such a polypeptide and such a polynucleotide are provided. a polynucleotide are provided. | 01-06-2011 |
| 20100322928 | METHODS OF DIAGNOSING, MONITORING TREATMENT AND TREATING SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) - A method of treating systemic lupus erythematosus (SLE) in a subject are provided. The method comprise altering in cells of the subject activity and/or expression of at least one gene selected from the group consisting of Mpo, Ltf, Lcn, Camp, Ngp, Slfn, Ctsg, Thbs1, S100a8, 1190003K14Rik, Prtn3, S100a9, Tfpi, Fzd6, Nid1, 5830484A20Rik, 5830484A20 LOC 545340, Tnfsf4, IPstpip2, Pigr, 270022B06Rik, L5R-alpha, A130040M12Rik, Gpr132, Cd8b1, Dhx9, Cyp11a1, Lmo7, Rnf184, Pstpip2, Hdgfrp3, Ass1 and Zbtb20, thereby treating SLE. Also provided are methods of diagnosing SLE and monitoring treatment of SLE. | 12-23-2010 |
| 20100312072 | METHOD AND SYSTEM FOR DETECTING AND GRADING PROSTATE CANCER - A method of estimating a grade of a prostate cancer from zinc data associated with the prostate, the zinc data being arranged gridwise in a plurality of picture-elements representing a zinc map of the prostate. The method comprises, clustering the zinc map according to zinc levels associated with the picture-elements, and estimating a cancer grade of at least one tissue region, based, at least in part, on zinc levels associated with a cluster of picture-elements representing the tissue region. | 12-09-2010 |
| 20100291127 | TUMOR ASSOCIATED ANTIGEN PEPTIDES AND USE OF SAME AS ANTI-TUMOR VACCINES - The present invention relates to tumor associated antigen (TAA) peptides and to use of same, of polynucleotides encoding same and of cells presenting same as anti-tumor vaccines. More particularly, the present invention relates to tumor associated antigen peptides derived from Uroplakin Ia, Ib, II and III, Prostate specific antigen (PSA), Prostate acid phosphatase (PAP) and Prostate specific membrane antigen (PSMA), BA-46 (Lactadherin), Mucin (MUC-1), and Teratocarcinoma-derived growth factor (CRIPTO-1) and the use of same as anti-tumor vaccines to prevent or cure bladder, prostate, breast or other cancers, carcinomas in particular. Most particularly, the present invention relates to tumor associated antigen peptides which are presentable to the immune system by HLA-A2 molecules. | 11-18-2010 |
| 20100279359 | TEMPLATE-DEPENDENT NUCLEIC ACID POLYMERIZATION USING OLIGONUCLEOTIDE TRIPHOSPHATES BUILDING BLOCKS - A novel use of a template-dependent polymerase. The novel use is effected by employing the template-dependent polymerase for incorporating at least one oligonucleotide triphosphate onto a nascent oligonucleotide-3′-OH in a template-dependent manner. | 11-04-2010 |
| 20100279302 | METHODS OF PREDICTING PAIRABILITY AND SECONDARY STRUCTURES OF RNA MOLECULES - Provided are methods of predicting a pairability of nucleotides of a plurality of RNA polynucleotides by (a) simultaneously determining a paired state or an unpaired state of nucleotides of the plurality of RNA polynucleotides; and (b) corresponding the paired state or the unpaired state of the nucleotides to a database of nucleic acid sequences, the database comprises nucleic acid sequences representing the plurality of RNA polynucleotides, thereby determining the pairability of nucleotides of the plurality of RNA polynucleotides. Also provided are methods of determining a secondary structure of a plurality of RNA molecules; methods of determining if a molecule is capable of modulating a secondary structure of at least one RNA polynucleotide of a plurality of RNA polynucleotides; and methods of screening for a marker associated with a pathology. | 11-04-2010 |
| 20100278853 | CONSTRAINED HIV V3 LOOP PEPTIDES AS NOVEL IMMUNOGENS AND RECEPTOR ANTAGONISTS - The present invention provides constrained peptides and other organic molecules, that mimic the three dimensional characteristics of the HIV-1 V3 loop peptide when bound by a highly potent human neutralizing monoclonal antibody specific for a V3 conformational epitope, which structure is determined by NMR. Methods for screening for, and designing such molecules are disclosed. These molecules are useful as immunogens for inducing broadly-neutralizing antibodies against HIV-1 as well as antagonists for inhibiting the binding of HIV-1 to the relevant co-receptors, and may therefore be used in method of preventing or treating HIV-1 infection and disease. | 11-04-2010 |
| 20100270228 | Methods, Compositions And Devices For Maintaining Chemical Balance Of Chlorinated Water - A composition-of-matter for use in water treatment, composed of a water-insoluble matrix and one or more amidohydrolase, such as cyanuric acid amidohydrolase, incorporated in or on the matrix, is disclosed. Also disclosed are devices containing same and methods utilizing same for water treatment. The water treatment is effected by an enzymatically-catalyzed reduction of the concentration of an amide-containing compound, such as cyanuric acid, found in chlorinated water of swimming polls, spas and other similar structures. | 10-28-2010 |
| 20100259546 | MODELIZATION OF OBJECTS IN IMAGES - A system includes an aligner to align an initial position of an at least partially kinematically, parameterized model with an object in an image, and a modelizer to adjust parameters of the model to match the model to contours of the object, given the initial alignment. An animation system includes a modelizer to hierarchically match a hierarchically rigid model to an object in an image, and a cutter to cut said object from said image and to associate it with said model. A method for animation includes hierarchically matching a hierarchically rigid model to an object in an image, and cutting said object from said image to associate it with said model. | 10-14-2010 |
| 20100221270 | THERAPEUTIC TRANSPLANTATION USING DEVELOPING, HUMAN OR PORCINE, RENAL OR HEPATIC, GRAFTS - A method of treating a renal, hepatic or enzyme-deficiency disorder in a subject in need thereof is disclosed. The method is effected by transplanting into the subject tissue derived from a human or porcine, kidney or liver, the kidney or liver being at a selected gestational stage. | 09-02-2010 |
| 20100204091 | SIVA Ubiquitination and/or Degradation-Related Activity and Modulators Thereof - The present invention relates to the ubiquitination and/or degradation-related activity of a SIVA polypeptide and to agents capable of modulating said activity. | 08-12-2010 |
| 20100193407 | Device and Method For Particle Manipulation in Fluid - A device for manipulating particles present in a fluid medium is disclosed. The device comprises a planar substrate, formed with at least one primary microchannel to allow passage of the fluid medium therethrough. The primary microchannel(s) has walls and a base and being in fluid communication with a plurality of secondary microchannels via at least one branching point. The device further comprises one or more ultrasound transmission pairs, positioned at opposite sides of the walls to generate ultrasound waves propagating through the fluid medium, substantially parallel to the planar substrate, such as to form a standing wave within the primary microchannel. | 08-05-2010 |
| 20100189750 | METHODS OF TREATING TUMORS IN IMMUNE-PRIVILEGED SITES - A method of treating cancer in an immune-privileged site of a subject in need thereof is provided. The method comprises systemically administering to an area outside the immune-privileged site of the subject, a therapeutically effective amount of naive, viable cells of a tumor of the subject, the tumor being in the immune-privileged site so as to generate an immune response in the subject, thereby treating the cancer in the immune-privileged site of the subject. | 07-29-2010 |
| 20100135974 | REDIRECTED, GENETICALLY-ENGINEERED T REGULATORY CELLS AND THEIR USE IN SUPPRESSION OF AUTOIMMUNE AND INFLAMMATORY DISEASE - A redirected Treg cell is endowed with specificity toward a selected target antigen or ligand. The cell contains a chimeric receptor polypeptide that is expressed in a single, continuous chain, with an extracellular recognition region displayed on the surface of the cell, a transmembrane region and an intracellular signaling region. The extracellular recognition region is specific for the selected target antigen or ligand. The intracellular signaling region includes a combination of T-cell signaling polypeptide moieties, which combination, upon binding of the extracellular recognition region to the selected target antigen or ligand, triggers activation of the redirected Treg cells to cause suppression of T-cell mediated immunity. Such redirected Treg cells may be used to suppress undesired activity of T effector cells thereby mediating an immune or inflammatory response. They are particularly useful in treating T effector cell-mediated diseases, such as inflammatory bowel disease, transplant rejection and GVH disease. | 06-03-2010 |
| 20100135953 | Method of treatment of age-related macular degeneration - The invention provides methods and compositions for treatment of age-related macular degeneration, which comprises causing T cells that produce IL-4 to accumulate in the eye by administration of an agent such as Copolymer-1, IL-4, cells activated with IL-4, IL-13 or up to 20 ng/ml IFN-g, or a pathogenic self-antigen associated with a T-cell-mediated specific autoimmune disease of the eye or a peptide derived therefrom, and any combination of such agents. | 06-03-2010 |
| 20100099627 | NUCLEAR TARGETING SEQUENCES - Isolated peptides comprising nuclear targeting activity or being capable of preventing endogenous nuclear targeting activity are disclosed. Polynucleotides encoding same, pharmaceutical compositions comprising same, as well as uses thereof are also disclosed. | 04-22-2010 |
| 20100099118 | METHODS OF DETERMINING TOTAL PON1 LEVEL - A method of determining an amount of total PON1 in a sample of a subject is disclosed. The method comprises:
| 04-22-2010 |
| 20100087363 | GLYCAN MODIFIED SOLUBLE RECEPTORS AND BINDING PROTEIN AND THEIR USE - An invention relates to a glycan-modified soluble receptor or binding protein of a cytokine, growth factor, lipoprotein or oxidized lipoprotein, modified to carry a terminal Gal, GlcNAc or GalNAc. | 04-08-2010 |
| 20100069478 | ISOFLAVONE DERIVATIVES AND USES THEREOF - Isoflavone derivatives are provided comprising a carboxyalkylene moiety linked via its alkylene chain to the aromatic ring and via its carboxy group to an aminoalkyleneamino residue, which, in turn, is covalently linked to a functional group B. The isoflavone derivatives are preferably derived from biochanin A, genistein, and daidzein, and the functional group B is preferably an amino protecting group. These isoflavone derivatives are useful for treating or preventing diseases or disorders associated with estrogen receptor functioning. | 03-18-2010 |
| 20100048863 | GROWTH FACTOR WHICH ACTS THROUGH ERB B-4 RTK - A method of diagnosing a disease or syndrome associated with disregulation of Neuregulin-4 (NRG-4), Aa novel ErbB-4 ligand, referred to herein as Neuregulin-4 (NRG-4)in a subject is disclosed. The method comprising: (a) obtaining a sample from a subject; (b) incubating the sample with at least one oligonucleotide or oligonucleotide analog of at least bases, said oligonucleotide or oligonucleotide analog capable of hybridizing to a portion of a polynucleotide strand encoding NRG-4 to thereby diagnosing the disease, condition or syndrome associated with disregulation of NRG-4. | 02-25-2010 |
| 20100041043 | METHOD FOR THE DIAGNOSIS AND FOLLOW-UP OF SCHIZOPHRENIA AND OTHER MENTAL AND NEUROLOGICAL DISORDERS - A method for the diagnosis and follow up of a mental disorder or of a neurodegenerative disorder in an individual, comprises: (i) measuring mRNA of D | 02-18-2010 |
| 20100029758 | DERIVATIVES OF ISOFLAVONES - The present invention discloses novel isoflavone conjugates and their use for affinity targeting of drugs, imaging and detection agents to cells having estrogen receptors, particularly estrogen receptors subtype β. | 02-04-2010 |
| 20100021489 | Nucleic acid molecules, polypeptides, antibodies and compositions for treating and detecting influenza virus infection - Polynucleotides and polypeptides which participate in influenza virus infection of cells and nucleic acid molecules, which include a polynucleotide sequence capable of specifically binding the polypeptides of the present invention. Also provided are methods of using such nucleic acid molecules, polynucleotides and antibodies directed thereagainst for diagnosing, treating and preventing influenza virus infection. | 01-28-2010 |
| 20100021433 | Disease treatment via developing non-syngeneic graft transplantation - A method of providing a pancreatic, lymphoid/hematopietic or pulmonary organ and/or tissue function to a mammalian subject is provided. The method comprises transplanting into the subject a developing mammalian pancreatic, lymphoid/hematopietic or pulmonary organ/tissue graft, respectively, thereby generating a functional pancreatic, lymphoid/hematopietic or pulmonary organ and/or tissue, respectively, for providing the pancreatic, lymphoid/hematopietic or pulmonary organ and/or tissue function, respectively, to the subject. | 01-28-2010 |
| 20100003751 | Methods of generating glial and neuronal cells and use of same for the treatment of medical conditions of the cns - A method of generating neural and glial cells is provided. The method comprising growing human stem cells under conditions which induce differentiation of said human stem cells into the neural and glial cells, said conditions comprising the presence of retinoic acid and an agent capable of down-regulating Bone Morphogenic Protein activity. | 01-07-2010 |
| 20090324607 | Therapeutic Transplantation Using Developing, Human or Porcine, Renal or Hepatic, Grafts - A method of treating a renal, hepatic or enzyme-deficiency disorder in a subject in need thereof is disclosed. The method is effected by transplanting into the subject tissue derived from a human or porcine, kidney or liver, the kidney or liver being at a selected gestational stage. | 12-31-2009 |
| 20090318346 | BIVALENT ErbB LIGAND BINDING MOLECULES AND METHODS FOR THEIR PREPARATION AND USE - A new bivalent ErbB-based ligand binding molecule is disclosed along with its method of preparation and use. The binding molecule can be a protein expressed from a recombinant DNA molecule. The protein can contain two extracellular domains of an ErbB receptor that both bind to ErbB receptor ligands. These binding molecules act as traps to bind and sequester ligands, thus making them unavailable for binding to cellular ErbB receptors. | 12-24-2009 |
| 20090305954 | HISTIDINE-CONTAINING DIASTEREOMERIC PEPTIDES AND USES THEREOF - Diastereomeric peptides with a net positive charge greater than +1, and cyclic derivatives thereof, are provided, having at least 13 amino acid residues, comprising histidine and one or more hydrophobic amino acid residues, optionally esterified or amidated at the C-terminus and/or acylated at the N-terminus. The peptides may contain other amino acid residues including non-natural amino acids. The peptides are particularly useful in the treatment of cancer. | 12-10-2009 |
| 20090297515 | Use of Caspase-8 Inhibitors for Modulating Hematopoiesis - A method of inhibiting hematopoiesis in a subject is provided. The method is effected by downregulating an expression or activity of caspase-8 in the subject thereby inhibiting hematopoiesis therein. | 12-03-2009 |
| 20090292482 | Methods and Systems for Generating Cell Lineage Tree of Multiple Cell Samples - A method of generating a cell lineage tree of a plurality of cells of an individual is provided. The method comprising: (a) determining at least one genotypic marker for each cell of the plurality of cells; and (b) computationally clustering data representing the at least one genotypic marker to thereby generate the cell lineage tree of the plurality of cells of the individual. | 11-26-2009 |
| 20090291888 | MODULATORS OF TNF RECEPTOR ASSOCIATED FACTOR (TRAF), THEIR PREPARATION AND USE - A DNA sequence encoding a protein capable of binding to a tumor necrosis factor receptor-associated factor (TRAF) molecule, TRAF-binding proteins, their isoforms, analogs, fragments and derivatives encoded by the DNA sequence, their methods for the production of the DNA sequences and proteins, and the uses for the DNA sequence and proteins. | 11-26-2009 |
| 20090269331 | CASPASE-8 AND INFLAMMATION, INFECTION AND WOUND HEALING - The present invention relates to the regulatory role of caspase-8 in infection by intracellular pathogen, inflammation and wound healing | 10-29-2009 |
| 20090263354 | Compositions and siRNAs for inhibiting C/EBPbeta - The invention relates to C/EBPβ and modulation of cell resistance or sensitivity to triggers of cell death. More particular, it provides pharmaceutical compositions and siRNAs for inhibiting C/EBPβ thus decreasing resistance or enhancing sensitivity of cancer cells to a cancer therapy. | 10-22-2009 |
| 20090258790 | IDENTIFYING ANTIGEN CLUSTERS FOR MONITORING A GLOBAL STATE OF AN IMMUNE SYSTEM - Method, system and an article of manufacture for clustering and thereby identifying predefined antigens reactive with undetermined immunoglobulins of sera derived from patient subjects in need of diagnosis of disease or monitoring of treatment. | 10-15-2009 |
| 20090239799 | Pharmaceutical Compositions Comprising Ccl2 and Use of Same For The Treatment of Inflammation - A method of treating an inflammation in a subject thereof is provided. The method comprising administering to the subject a therapeutically effective amount of CCL2, thereby treating the inflammation. Also provided are pharmaceutical compositions and unit dosage forms which comprise CCL2 for the treatment of inflammation. | 09-24-2009 |
| 20090232774 | Universal donor-derived tolerogenic cells for inducing non-syngeneic transplantation tolerance - The present invention provides a method of treating a disease in a subject in need thereof via non-syngeneic graft administration without or with reduced concomitant graft rejection. The method comprises administering to the subject a therapeutically effective graft being non-syngeneic with the subject, and a dose of tolerogenic cells being non-syngeneic with both the subject and the graft for preventing or reducing graft rejection in the subject, thereby treating the disease in the subject | 09-17-2009 |
| 20090214470 | EYE-DROP VACCINE CONTAINING COPOLYMER 1 FOR THERAPEUTIC IMMUNIZATION - The invention provides an eye-drop vaccine for therapeutic immunization of a mammal comprising Copolymer 1, a Copolymer 1-related peptide, or a Copolymer 1-related polypeptide, for treating neuronal degeneration caused by an injury or disease, disorder or condition in the central nervous system (CNS) or peripheral nervous system (PNS), for preventing or inhibiting neuronal secondary degeneration which may otherwise follow primary injury in the CNS, for promoting nerve regeneration in the CNS or in the PNS after an injury, disease, disorder or condition or for protecting CNS and PNS cells from glutamate toxicity. | 08-27-2009 |
| 20090208510 | Antibodies and pharmaceutical compositions containing same useful for inhibiting activity of metalloproteins - A method of producing a metalloprotein inhibitor, the method comprising generating antibodies directed at a composition including a metal ion-bound chelator, wherein the composition is selected having structural and electronic properties similar to a functional domain of the metalloprotein, thereby producing the metalloprotein inhibitor. | 08-20-2009 |
| 20090208506 | Antibodies against flagellin and uses thereof - The present invention provides a novel class of monoclonal antibodies which have a high affinity, broad spectrum neutralizing reactivity to flagellin from various Gram-negative bacteria including, but not limited to, | 08-20-2009 |
| 20090191162 | Catecholamine Receptor Modulation - The invention relates to receptors of catecholamines and their role in stem cell development and function. | 07-30-2009 |
| 20090155288 | Methods of identifying combinations of antibodies with an improved anti-tumor activity and compositions and methods using the antibodies - A method of identifying a combination of antibodies with a combined improved anti tumor activity is provided. The method comprising identifying at least two anti RTK antibodies capable of inducing synergistic endocytosis of the RTK in a cell expressing the RTK, thereby identifying the combination of antibodies with the combined improved anti-tumor activity. | 06-18-2009 |
| 20090137999 | METHOD OF AND SYSTEM FOR SELECTIVE CELL DESTRUCTION - Method and apparatus for the ionization of living cells where an optical device ( | 05-28-2009 |
| 20090136462 | TUMOR ASSOCIATED ANTIGEN PEPTIDES AND USE OF SAME AS ANTI-TUMOR VACCINES - The present invention relates to tumor associated antigen (TAA) peptides and to use of same, of polynucleotides encoding same and of cells presenting same as anti-tumor vaccines. More particularly, the present invention relates to tumor associated antigen peptides derived from Uroplakin Ia, Ib, II and III, Prostate specific antigen (PSA), Prostate acid phosphatase (PAP) and Prostate specific membrane antigen (PSMA), BA-46 (Lactadherin), Mucin (MUC-1), and Teratocarcinoma-derived growth factor (CRIPTO-1) and the use of same as anti-tumor vaccines to prevent or cure bladder, prostate, breast or other cancers, carcinomas in particular. Most particularly, the present invention relates to tumor associated antigen peptides which are presentable to the immune system by HLA-A2 molecules. | 05-28-2009 |
| 20090127208 | ZERO VALENT METAL COMPOSITE, MANUFACTURING, SYSTEM AND METHOD USING THEREOF, FOR CATALYTICALLY TREATING CONTAMINATED WATER - Zero valent metal composite, manufacturing thereof, using thereof, and system including thereof, for (in-situ or ex-situ) catalytically treating contaminated water, such as sub-surface water, surface water, above-surface water, water vapor, or/and gaseous water. Composite includes powdered diatomite matrix incorporated with nanometer (1-1000 nm) sized particles of a zero valent (transition) metal (iron, cobalt, nickel, copper, zinc, palladium, platinum, or/and gold) and at least one electron transfer mediator (catalyst) from porphyrinogenic organometallic complexes (e.g., metalloporphyrins (chlorophylls, hemes, cytochromes) or metallocorrins (e.g., vitamin B | 05-21-2009 |
| 20090124564 | Compositions and methods for regulating apoptosis - Methods and pharmaceutical compositions for regulating apoptosis and treating pathologies associated with disregulated apoptosis are provided. Specifically the present invention provides agents capable of modulating the expression of an MCD-containing protein (e.g., Mtch2) capable of tBID binding activity and/or the tBID binding activity of the MCD-containing protein. | 05-14-2009 |
| 20090124557 | Compositions and methods for treating cancer - A composition which comprises a chimeric polypeptide is provided. The chimeric polypeptide having a flagellin amino acid sequence and a mucin 1 amino acid sequence which includes at least a 7 amino acid sequence of the mucin 1 tandem repeat which can be used to elicit an immune response against MUC1—expressing cancerous cells. Also provided is a method of treating cancer such as a cancer of a glandular epithelium in which MUC1 is overexpressed using the composition of the present invention. | 05-14-2009 |
| 20090104175 | USE OF CASPASES FOR THE PREPARATION OF MEDICAMENTS - The invention relates to caspases and to extracellular use of caspases for regulating cell functions. | 04-23-2009 |
| 20090098116 | IMMUNOGENIC COMPOSITIONS FOR INDUCTION OF ANTI-TUMOR IMMUNITY - The invention relates to the use of an immunogen selected from the group consisting of | 04-16-2009 |
| 20090088558 | TNF RECEPTOR ACTION MODULATION - A method of modulating signal transduction and/or cleavage in Tumor Necrosis Factor Receptors (TNF-Rs) is provided. Peptides or other molecules may interact either with the receptor itself, or with effector proteins interacting with the receptor, thus modulating the normal functioning of the TNF-Rs. Such peptides or other molecules may be employed for prophylactic and therapeutic applications in TNF associated diseases. | 04-02-2009 |
| 20090081697 | Methods of growing crystals of free and antibiotic complexed large ribosomal subunits, and methods of rationally designing or identifying antibiotics using structure coordinate data derived from such crystals - Methods of growing crystals of free and antibiotic complexed large ribosomal subunits, coordinates defining the 3D atomic structure thereof and methods of utilizing such coordinates for rational design or identification of antibiotics or large ribosomal subunits having desired characteristics are disclosed. | 03-26-2009 |
| 20090075889 | IREN PROTEIN, ITS PREPARATION AND USE - There are provided DNA sequences encoding TRAF binding proteins, proteins encoded thereby, and their use in the treatment or prevention of pathological conditions associated with NF-κB induction, or an activity mediated by a TRAF. | 03-19-2009 |
| 20090058428 | Method and device for monitoring and controlling fluid locomotion - A device for monitoring dripping of a fluid from a fluid channel, the device comprises a capacitor, being formed on or integrated with the fluid channel, and electrical contacts, connecting the capacitor to a capacitance measuring device, the capacitor is designed and constructed so that a change in a capacitance thereof represents a formation of a drop near an edge of the fluid channel. | 03-05-2009 |
| 20090042796 | DERIVATIVES OF THE IL-2 RECEPTOR GAMMA CHAIN, THEIR PRODUCTION AND USE - This invention relates to the use of the IL-2 common gamma (cγc) and related molecules for the modulation of signal activities controlled by NIK, and some new such molecules | 02-12-2009 |
| 20090036380 | Composition And Method For Brain Tumor Therapy - A method of treating a disease associated with abnormal apoptosis in a subject in need thereof is disclosed. The method comprises administering to the subject a therapeutically effective amount of at least one agent capable of increasing and/or stabilizing an interaction between at least an active portion of TrkA and at least an active portion of Karet, thereby treating the disease in the subject. | 02-05-2009 |
| 20090010873 | Methods of Cell Therapy, Neurogenesis and Oligodendrogenesis - A method is provided for inducing and enhancing neurogenesis and/or oligodendrogenesis from endogenous as well as from exogenously administered stem cells, which comprises administering to an individual in need a neuroprotective agent such as a nervous system (NS)-specific antigen, a peptide derived therefrom, T cells activated therewith, poly-YE, microglia activated by IFN-γ and/or IL-4 and combinations thereof. The method includes stem cell therapy in combination with the neuroprotective agent. | 01-08-2009 |
| 20080311599 | ANTIBODIES AGAINST CASPASE-8, THEIR PREPARATION AND USE - The invention relates to antibodies to a specific region in caspase-8, and to their use. | 12-18-2008 |
| 20080305097 | Use of Protease or a Protease Inhibitor for the Manufacture of Medicaments - The invention relates to the use of a cathepsin K inhibitor (CTKI) or CTK, a mutein, isoform, fused protein, functional derivative, active fraction, circularly permutated derivative, a salt or inducer thereof in the manufacture of a medicament for treating a disease in which SDF-1 activity and/or concentration is involved with the development and/or course of the disease. | 12-11-2008 |
| 20080279869 | METHOD FOR REDUCING NEURONAL DEGENERATION BY ADMINISTERING CNS-DERIVED PEPTIDES OR ACTIVATED T CELLS - Compositions are provided for promoting nerve regeneration or reducing or inhibiting degeneration in the CNS or PNS to ameliorate the effects of injury or disease. The composition includes an active ingredient selected from:(a) a peptide obtained by modification of a self-peptide derived from a CNS-specific antigen, which modification consists in the replacement of one or more amino acid residues of the self-peptide by different amino acid residues, such modified CNS peptide still being capable of recognizing the T-cell receptor recognized by the self-peptide but with less affinity; (b) a nucleotide sequence encoding such a peptide; (c) T cells activated by such peptide; and (d) any combination of (a)-(c). The peptide is preferably obtained by modification of the self-peptide p87-99 of MBP, more preferably, by replacing lysine 91 with glycine (G91) or alanine (A91) or by replacing proline 96 with alanine (A96). | 11-13-2008 |
| 20080274998 | Disaccharide Molecules and Derivatives Thereof and Methods of Using Same - The present invention is of a method and compounds for mediating a biological activity mediated by moesin, and in particular, for such a method and compounds for mediating a biological activity that is capable of being mediated through binding of a disaccharide to moesin. | 11-06-2008 |
| 20080274102 | Antibodies to Nik, Their Preparation and Use - An antibody or antibody fragment preparation being capable of specifically binding the amino acid sequence 60-76, 86-98, 135-149, 215-227, 363-377, 385-397, 405-419, 427-440, 509-522, 605-619, 635-649, 666-680, 696-711, 752-766, 836-851, 871-884, and/or 904-916 of NIK, or being capable of specifically binding a specific portion of the amino acid sequence is provided. | 11-06-2008 |
| 20080267983 | Peptide Inhibitors for Mediating Stress Responses - The present invention relates to peptides capable of inhibiting cellular and immune stress responses in a eukaryotic cell. The invention provides compositions and methods for the treatment of human degenerative diseases and inflammation, utilizing peptides recognized by monoclonal anti-DNA antibodies, the peptides having anti-apoptotic and anti-inflammatory activity. The invention further provides antibody molecules and uses thereof for the isolation of such peptides. | 10-30-2008 |
| 20080267908 | Il-32 Modulators - The present invention relates to methods of screening for modulators of interleukin 32 (IL-32), to modulators of IL-32 and to their use. Proteinase 3 has been identified as an IL-32 binding protein capable of deavege thereof. Inhibition of PR 3 activity to process IL-32 or neutralization of IL-32 by-inactive PR3 or its fragments may reduce the consequences of IL-32 in immune regulated diseases (e.g. inflammatory diseases). | 10-30-2008 |
| 20080254028 | CASPASE-8 BINDING PROTEIN, ITS PREPARATION AND USE - The present invention relates to a caspase-8 interacting polypeptide (Cari), methods for its preparation, and its use. | 10-16-2008 |
| 20080233149 | Use of Erythropoietin for Enhancing Immune Responses and for Treatment of Lymphoproliferative Disorders - The present invention relates to the use of erythropoietin (EPO) for enhancing immune responses and for the treatment of lymphoproliferative disorders, excluding multiple myeloma. Accordingly to the invention EPO may be administered with a viral or bacterial vaccine. | 09-25-2008 |
| 20080233099 | Method and composition for protecting neuronal tissue from damage induced by elevated glutamate levels - A method of reducing extracellular brain glutamate levels. The method comprises administering to a subject in need thereof a therapeutically effective amount of an agent capable of reducing blood glutamate levels thereby reducing extracellular brain glutamate levels. | 09-25-2008 |
| 20080233096 | Method and composition for protecting neuronal tissue from damage induced by elevated glutamate levels - A method of reducing extracellular brain glutamate levels. The method comprises administering to a subject in need thereof a therapeutically effective amount of an agent capable of reducing blood glutamate levels thereby reducing extracellular brain glutamate levels. | 09-25-2008 |
| 20080232156 | Method using a synthetic molecular spring device in a system for dynamically controlling a system property and a corresponding system thereof - Using a synthetic molecular spring device in a system for dynamically controlling a system property, such as momentum, topography, and electronic behavior. System features (a) the synthetic molecular spring device having (i) at least one synthetic molecular assembly each featuring at least one chemical unit including at least one: (1) atom; (2) complexing group complexed to at least one atom; (3) axial ligand reversibly physicochemically paired with at least one complexed atom; and (4) substantially elastic molecular linker; and, (ii) an activating mechanism directed to at least one atom-axial ligand pair; and, (b) a selected unit operatively coupled to synthetic molecular assembly, and exhibiting the system property. Activating mechanism sends an activating signal to atom-axial ligand pairs, for physicochemically modifying atom-axial ligand pairs, thereby activating at least one cycle of spring-type elastic reversible transitions between contracted and expanded linear conformational states of substantially elastic molecular linkers, causing dynamically controllable change in the system property. | 09-25-2008 |
| 20080215301 | Method and apparatus for predicting protein structure - A method of determining predicting putative contacting sites of a target protein is disclosed. The method uses a substitution matrix for calculating contact probabilities for pairs of columns in a sequence alignment containing the amino acid sequence of the target protein. The contact probabilities can also be used for predicting the three-dimensional structure of the protein. The putative contacts and/or three-dimensional structure typically correspond to the hydrophobic core of the target protein. | 09-04-2008 |
| 20080199895 | Highly purified and stabilized Na,K-ATPase isoforms and methods of producing same - A composition of matter comprising active Na,K-ATPase is disclosed, each Na,K-ATPase comprising an α and β subunit, the Na,K-ATPase being at least 85% purified. Methods of purifying same and uses thereof are also disclosed. | 08-21-2008 |
